Product
177Lu-FAP-2286
1 clinical trial
1 indication
Indication
Solid TumorClinical trial
LuMIERE: A Phase 1/2, Multicenter, Open-label, Non-randomized Study to Investigate Safety and Tolerability, Pharmacokinetics, Dosimetry, and Preliminary Activity of 177Lu-FAP-2286 in Patients With an Advanced Solid TumorStatus: Active (not recruiting), Estimated PCD: 2026-06-30